Global News

[ad_1] Next week is one of the biggest of the year for health-care investors, and it has historically been a good time to own ETFs that track the industry. The 2023 JPMorgan Health Care Conference is set to kick off next Monday in San Francisco. The event features keynote speeches from the CEOs of Sage Therapeutics and Eli Lilly , as well as presentations from dozens of other health-care and biotech companies. The conference typically sees many companies preannounce quarterly results, revise outlooks and update investors about clinical trials. While those updates can break both ways for individual companies, they have recently been good news for the sector as a whole. Over the past five years, many of the biggest ETFs in health care and biotech have seen an average positive return in the first half of January, when the conference is typically held. The three funds below — the SPDR S & P Biotech ETF (XBI) , the Health Care Select Sector SPDR Fund (XLV) and the iShares U.S. Medi

[ad_1] Investors hoping to capture more upside from artificial intelligence could turn to a sector that's underperformed this year, and maybe not immediately associated with AI: Health care. A handful of large tech names surged in the first half thanks to a mania for all things tied to artificial intelligence. Apple, for example, last week closed with a $3 trillion market capitalization for the first time. Nvidia is up by nearly 200% in 2023. Going forward, some of those gains might spill over to health care, which has underperformed this year. The sector is the third weakest out of 11 in the S & P 500, down about 3% year to date. "A lot of people talk about AI-powered performance and how that's going to impact the tech sector. And I think that's well understood," said Jamie Cox, managing partner for Harris Financial Group. "But what a lot of people fail to appreciate is that artificial intelligence and quantum computing are actually going to have th